MF1 Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.019 |
| 52 Week High | HK$0.12 |
| 52 Week Low | HK$0.019 |
| Beta | -0.52 |
| 11 Month Change | -35.00% |
| 3 Month Change | -27.78% |
| 1 Year Change | -83.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| MF1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.3% | 0.8% | -1.3% |
| 1Y | -83.3% | -17.5% | 7.4% |
Return vs Industry: MF1 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: MF1 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| MF1 volatility | |
|---|---|
| MF1 Average Weekly Movement | 26.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MF1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MF1's weekly volatility has increased from 21% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 93 | James Qun Xue | www.canbridgepharma.com |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
| MF1 fundamental statistics | |
|---|---|
| Market cap | €8.80m |
| Earnings (TTM) | -€53.77m |
| Revenue (TTM) | €13.79m |
0.6x
P/S Ratio-0.2x
P/E RatioIs MF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MF1 income statement (TTM) | |
|---|---|
| Revenue | CN¥104.61m |
| Cost of Revenue | CN¥37.69m |
| Gross Profit | CN¥66.92m |
| Other Expenses | CN¥474.87m |
| Earnings | -CN¥407.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 63.97% |
| Net Profit Margin | -389.95% |
| Debt/Equity Ratio | -16.3% |
How did MF1 perform over the long term?
See historical performance and comparison